Adagio Medical Holdings, Inc. ADGM PHARMA
Company Overview
Adagio Medical Holdings, Inc., a medical technology company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, and ventricular tachycardia. The company's product portfolio includes iCLAS atrial ultra-low temperature ablation (ULTA) catheter and system; vCLAS ventricular ULTC catheter; and Cryopulse pulsed field cryoablation catheters. Adagio Medical Holdings, Inc. was founded in 2011 and is headquartered in Laguna Hills, California.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | -52.17% |
| 6 Months: | -38.39% |
| 3 Months: | -18.35% |
| 1 Month: | -11.18% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)53.66 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 74.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ADGM Adagio Medical Holdings, Inc. PHARMA | 0.61 | -0.45 | $13.55M | 0.00% | -62.51% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 41.00K | 26.00K | 254.00K | 132.00K | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | 253.00K | 342.00K | 31.00K | 58.00K | 0 |
| Gross Profit | - | - | - | - | -253.00K | -342.00K | -31.00K | -58.00K | 0 |
| Operating Expenses | - | - | - | - | 7.14M | 4.38M | 5.69M | 3.91M | 5.20M |
| Operating Income | -9.08M | -8.81M | -6.66M | -4.42M | -7.40M | -4.72M | -5.72M | -3.97M | -5.20M |
| EBITDA | - | - | - | - | -6.78M | -2.96M | -9.18M | -2.29M | -6.01M |
| Interest Expense | - | - | - | - | 662.00K | 720.00K | 749.00K | 775.00K | 778.00K |
| Pretax Income | - | - | - | - | -7.71M | -3.95M | -10.12M | -3.31M | -7.00M |
| Tax Provision | - | - | - | - | - | - | - | - | - |
| Net Income | -10.76M | -8.02M | -5.73M | 3.61M | -7.71M | -3.95M | -10.12M | -3.31M | -7.00M |
| Diluted EPS | -14.15 | -10.28 | -7.35 | 0.02 | -0.51 | -0.35 | -0.66 | -0.21 | -0.31 |
| R&D Expense | 4.42M | 3.47M | 2.87M | 1.22M | 3.66M | 1.97M | 2.77M | - | 2.74M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 270.00K | 189.00K | 300.00K | 0 |
| Cost of Revenue | 1.16M | 875.00K | 1.31M | 684.00K |
| Gross Profit | -888.00K | -686.00K | -1.01M | -684.00K |
| Operating Expenses | 19.76M | 23.23M | 26.94M | 21.21M |
| Operating Income | -20.64M | -23.91M | -27.94M | -21.89M |
| EBITDA | -19.60M | -23.04M | -35.95M | -21.21M |
| Interest Expense | 0 | 137.00K | 1.66M | 2.91M |
| Pretax Income | -19.94M | -23.67M | -38.15M | -25.08M |
| Tax Provision | - | - | - | - |
| Net Income | -19.94M | -23.67M | -38.15M | -25.08M |
| Diluted EPS | -1.49 | -1.77 | -2.85 | -1.51 |
| R&D Expense | - | - | 15.40M | 10.64M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Jul 2024 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | 8.70M | 6.83M | - | 48.45M | 43.25M |
| Current Assets | - | 6.73M | 5.18M | - | 25.35M | 20.08M |
| Cash & Equivalents | - | 5.55M | 1.38M | - | 20.59M | 17.11M |
| Inventory | - | 367.00K | 3.32M | - | 2.57M | 1.67M |
| Receivables | - | 0 | 71.00K | - | 35.00K | 0 |
| Total Liabilities | - | 104.57M | 138.85M | - | 28.54M | 30.85M |
| Current Liabilities | - | 12.97M | 47.18M | - | 7.76M | 8.23M |
| Long Term Debt | - | - | 143.00K | - | 16.08M | 21.04M |
| Total Debt | - | 9.80M | 38.40M | - | 16.27M | 21.76M |
| Total Equity | - | -95.88M | -132.02M | -148.31M | 19.91M | 12.40M |
| Shares Outstanding | - | 13.39M | 14.54M | - | 15.20M | 22.21M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -19.31M | -22.41M | -25.65M | -19.01M |
| Investing Cash Flow | -1.27M | -500.00K | -340.00K | -374.00K |
| Financing Cash Flow | 130.00K | 9.53M | 21.88M | 16.13M |
| Capital Expenditure | -1.27M | -502.00K | -340.00K | -374.00K |
| Free Cash Flow | -20.58M | -22.91M | -25.99M | -19.39M |
| Net Change in Cash | -20.45M | -13.39M | -4.12M | -3.25M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | -328.9% | -363.0% | -335.3% | - |
| Operating Margin % | -7,646.3% | -12,652.4% | -9,314.0% | - |
| Net Margin % | -7,384.4% | -12,525.4% | -12,715.3% | - |
| ROE % | - | 24.7% | 28.9% | -202.3% |
| ROCE % | - | 559.9% | 69.2% | -62.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Perceptive Advisors Llc | 44.47% | 9.88M | $4.77M |
| 2 | Adage Capital Partners GP L.L.C. | 5.67% | 1.26M | $607.23K |
| 3 | Adar1 Capital Management, LLC | 5.43% | 1.21M | $581.63K |
| 4 | Alyeska Investment Group, L.p. | 5.22% | 1.16M | $559.51K |
| 5 | Sio Capital Management, LLC | 3.15% | 698.99K | $337.26K |
| 6 | SilverArc Capital Management, LLC | 1.01% | 224.36K | $108.25K |
| 7 | Shaolin Capital Management LLC | 0.77% | 171.17K | $82.59K |
| 8 | Vanguard Capital Management LLC | 0.49% | 108.95K | $52.57K |
| 9 | Geode Capital Management, LLC | 0.36% | 79.11K | $38.17K |
| 10 | Affinity Asset Advisors, Llc | 0.36% | 80.00K | $38.60K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ADGM
Adagio Medical Reports Second Quarter 2026 Results
LAGUNA HILLS, Calif., August 11, 2026--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial resul…
Adagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA System
LAGUNA HILLS, Calif., August 03, 2026--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the successful …
Small Cap Growth Virtual Investor Conference: Presentations Now Available for On-Demand Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the pre…
Small Cap Growth Virtual Investor Conference Agenda Announced for February 5th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the agenda fo…
ADGM — Frequently Asked Questions
What is the current share price of Adagio Medical Holdings, Inc. (ADGM)?
As of 2026-09-19 21:16 PDT, Adagio Medical Holdings, Inc. (ADGM) trades at $0.61 on NasdaqCM. Its 52-week range is $0.38 to $2.36.
What is the market capitalisation of ADGM?
Adagio Medical Holdings, Inc. (ADGM) has a market capitalisation of $13.55M on NasdaqCM.
What is the P/E ratio of ADGM?
ADGM trades at a trailing price-to-earnings (P/E) ratio of -0.45. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -31.84.
Is ADGM a good stock to buy?
This page provides a data-driven analysis of Adagio Medical Holdings, Inc. (ADGM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.